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ABSTRACT
Objective To assess temporal clinical and budget 
impacts of changes in atrial fibrillation (AF)- related 
prescribing in England.
Methods Data on AF prevalence, AF- related stroke 
incidence and prescribing for all National Health Service 
general practices, hospitals and registered patients 
with hospitalised AF- related stroke in England were 
obtained from national databases. Stroke care costs 
were based on published data. We compared changes 
in oral anticoagulation prescribing (warfarin or direct 
oral anticoagulants (DOACs)), incidence of hospitalised 
AF- related stroke, and associated overall and per- patient 
costs in the periods January 2011–June 2014 and July 
2014–December 2017.
Results Between 2011–2014 and 2014–2017, 
recipients of oral anticoagulation for AF increased 
by 86.5% from 1 381 170 to 2 575 669. The number 
of patients prescribed warfarin grew by 16.1% from 
1 313 544 to 1 525 674 and those taking DOACs by 
1452.7% from 67 626 to 1 049 995. Prescribed items 
increased by 5.9% for warfarin (95% CI 2.9% to 8.9%) 
but by 2004.8% for DOACs (95% CI 1848.8% to 
2160.7%). Oral anticoagulation prescription cost rose 
overall by 781.2%, from £87 313 310 to £769 444 
028, (£733,466,204 with warfarin monitoring) and 
per patient by 50.7%, from £293 to £442, giving an 
incremental cost of £149. Nevertheless, as AF- related 
stroke incidence fell by 11.3% (95% CI −11.5% to 
−11.1%) from 86 467 in 2011–2014 to 76 730 in 
2014–2017 with adjustment for AF prevalence, the 
overall per- patient cost reduced from £1129 to £840, 
giving an incremental per- patient saving of £289.
Conclusions Despite nearly one million additional 
DOAC prescriptions and substantial associated spending 
in the latter part of this study, the decline in AF- related 
stroke led to incremental savings at the national level.
INTRODUCTION
Atrial fibrillation (AF) is a common condition 
affecting around 2% of the general population, and 
it increases the risk of stroke fivefold.1 AF is thought 
to be the direct cause of around one- third of isch-
aemic strokes,2 and AF- related strokes constitute 
the most severe stroke subtype.3–5 Oral anticoagula-
tion reduces the risk of stroke in high- risk patients 
with non- valvular AF.6 Both available classes of 
oral anticoagulants—vitamin K antagonists (most 
commonly warfarin) and direct oral anticoagulants 
(DOACs)—effectively reduce the risk of stroke. 
Additionally, the international thresholds for 
starting oral anticoagulation in people with AF have 
been lowered7–9 and the use of oral anticoagulation 
has increased, while the incidence of AF- related 
stroke has decreased.10 11 Nevertheless, substan-
tial gaps remain in the numbers of eligible patients 
having AF diagnosed and being started on or main-
tained on appropriate oral anticoagulation.10 12 13
Given the rising prevalence of AF due to the 
ageing and increasingly multimorbid population, 
drug costs are a potentially important determinant 
of the wider implementation of oral anticoagula-
tion for stroke prevention. DOACs have been esti-
mated to account for 5% of the overall drug budget 
in England.14 Several analyses found that even with 
a substantial cost differential, DOACs would be 
cost- effective compared with other forms of oral 
anticoagulation and should be made available to 
patients.7 14–18 The National Institute for Health and 
Care Excellence (NICE) analysis, however, included 
the costs of replacing antiplatelet drugs, which are 
no longer recommended for patients with AF. Addi-
tionally, the evaluation coincided with a change in 
how stroke risk was assessed. Thus, there is a need 
to better understand the role of costs incurred by 
use of oral anticoagulation for AF- related stroke 
prevention at scale.
The UK is unique in that various national primary 
and secondary care databases exist in which 
prospectively collected data relating to clinical care 
and health outcomes over many years are collated 
and presented in consistent data fields. We used 
these data to investigate changes in the number of 
oral anticoagulation prescriptions and hospitalised 
AF- related stroke incidence, and the budget impacts 
of these changes.
METHODS
This was a nationwide, multisource, electronic 
health record study and an associated budget impact 
analysis of changes in the incidence of AF- related 
stroke and in the prescription of oral anticoagu-
lation for prophylaxis against stroke in patients 
with AF over the period 2011–2017. There was no 
public or patient involvement in this research.
Hospitalised AF-related stroke
The number of episodes of hospitalised AF- related 
stroke in England was accessed from the Hospital 
Episode Statistics (HES) data warehouse (copyright 
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NHS Digital 2018, http:// content. digital. nhs. uk/ hes), in which 
each patient is given a unique identifying code and all data 
connected with a hospital admission, outpatient appointment or 
attendance in an emergency department are recorded. Eligible 
patients had a primary diagnosis of stroke (ischaemic, haem-
orrhagic or unspecified) and a secondary diagnosis of AF from 
1 March 2010 to 28 February 2018 to ensure full coverage of 
the study period. Data were aggregated into weekly counts of 
the number of finished consultant episodes (total time a patient 
spends under the care of an individual consultant). Transfer to a 
different consultant team counts as a further episode, but may be 
tracked via the patient’s unique identifier. We counted episodes 
for transferred patients as replicate episodes and deleted them 
from each weekly record.
Stroke was defined according to the International Statistical 
Classification of Diseases and Related Health Problems, 10th 
edition (ICD-10) codes for ischaemic (I63.0–I63.9), haemor-
rhagic (I61.0–I61.9) and unspecified (I64.X) strokes. AF was 
defined with the ICD-10 code I48.X. Episodes of hospitalisa-
tion for patients with a primary diagnosis of non- traumatic 
intracranial bleeding (ICD-10 codes I60.0–I60.9, I62.0, I62.1 
and I62.9) and a secondary diagnosis of AF were also identi-
fied. Unless specified, for this study, stroke incidence represents 
AF- related stroke (stroke as the primary diagnosis and AF as the 
secondary diagnosis).
Prescribing and prescribing costs
Prescribing data for England were extracted from the Business 
Services Authorities electronic Prescribing and Costing Tool 
((ePACT) see online supplemental table S1). This national repos-
itory holds aggregated information about dispensed prescrip-
tions according to the British National Formulary classification 
system. It also provides volumes and associated costs by general 
practitioner (GP) practice. The total number of items prescribed 
and costs of all branded and unbranded warfarin and DOACs 
were collected for each GP practice for January 2011–December 
2017 (see online supplemental table S2). The search metrics 
were clinical commissioning group (CCG) each group commis-
sions healthcare for a specified region in England), GP practice, 
small geographical areas based on postal codes, and drug pack 
code, drug name, year, total cost, total net ingredient cost and 
average net ingredient cost per quantity (see online supplemental 
table S3).
AF prevalence
The national prevalence of AF was derived from the Clinical 
Domain of the Quality and Outcomes Framework (QOF) data-
base for England. QOF is a national database that collects annual 
prevalence and treatment data for several conditions, including 
AF, from all GP practices in England at the end of March each 
year. Data for the QOF years from 1 April 2010 to 31 March 
2018 were extracted to cover the entire study period.
Budget impact analysis
The per- patient healthcare costs in the first year following 
stroke were based on data from a UK study by Xu et al.1 The 
researchers included ambulance transport, MRI or CT scans, 
thrombolysis, acute stroke unit care, rehabilitation stroke unit 
care, general medical ward care, community rehabilitation, GP 
visits, secondary prevention and therapy for early supported 
discharge in the cost calculations where possible. They estimated 
a mean per- patient cost for care after acute stroke of £13 452, 
adjusted to 2017 values using the NHS Hospital and Community 
Health Service inflation index.19 This cost was congruent with 
that estimated by Youman et al20 of £12 228, which was used in 
the 2014 NICE guidance for the management of AF.7 The value 
£13 452 was used in this study as the cost of management in the 
first year after stroke.
Given that the clinical indication for oral anticoagulation 
is not stated in ePACT, we employed the methods used in the 
NICE anticoagulation therapy commissioning guide21 to calcu-
late the proportion of oral anticoagulants prescribed to treat AF 
and other disorders. For warfarin, first we extracted the annual 
prevalence of AF from QOF (range 1.5%–1.8%) and the annual 
prevalence of new venous thromboembolism (VTE), VTE 
needing long- term anticoagulation (0.3%) and other conditions 
requiring oral anticoagulation therapy (chronic rheumatic heart 
disease, antiphospholipid syndrome, cardiomyopathy and pros-
thetic heart valve; 0.37%) from the NICE commissioning guid-
ance21 (see online supplemental tables S4 and S5). Second, we 
derived the annual prevalence of oral anticoagulation use among 
patients with AF through the 2011–2016 data in the Guidance on 
Risk Assessment Stroke Prevention in AF tool (PRIMIS, Univer-
sity of Nottingham, Nottingham, UK). The annual percentages 
of anticoagulation prescribed took into account changes in the 
population of England, the prevalence of AF, VTE and other 
conditions, and the prescriptions of oral anticoagulants to 
patients with AF over that period (see online supplemental table 
S5). (Of note, the rate of prescribing of oral anticoagulants for 
VTE did not change between 2009 and 2015.22) For DOACs, we 
removed any doses that were not licensed for AF.
We extracted the annual number of prescriptions of oral 
anticoagulants per CCG from ePACT and applied the esti-
mated annual rate of those prescribed for AF to derive the total, 
warfarin and DOAC prescription rates for patients with AF. The 
costs associated with warfarin reflected the net ingredient cost as 
reported in ePACT. Warfarin doses are tailored depending on the 
international normalised ratio (INR). To estimate the cost of INR 
monitoring, the total dose in milligrams of warfarin prescribed 
per study year was divided by 365 to estimate the mean total 
daily dose. This was then divided by 4.5 (the mean treatment 
dose in milligrams as calculated by NICE3) to estimate the mean 
number of patients receiving warfarin. The default cost of INR 
testing used by NICE is £242 per patient7; therefore, we multi-
plied the mean number of patients by this value for each study 
year and summed the results. For DOACs, we used the NHS 
Electronic Drug Tariff basic prices per pack (see online supple-
mental table S3). The stroke- associated healthcare costs plus oral 
anticoagulant prescribing costs were calculated and compared 
for 2011–2014 and 2014–2017.
Analysis
The incidence of AF- related stroke, with and without standard-
isation for annual prevalence of AF reported in QOF, was esti-
mated annually over the study period. Stroke incidence, ranked 
by size of CCG, was compared for the periods January 2011–
June 2014 and July 2014–December 2017 to include sufficient 
numbers of strokes. The numbers of oral anticoagulant items 
prescribed for patients with AF are presented similarly.
Using Poisson regression models, we investigated whether, 
at the same time as change in warfarin and DOAC uptake, the 
incidence of AF- related stroke (all, ischaemic or haemorrhagic 
stroke) also changed. Prescription year, percentage of DOAC 
uptake for patients with AF and AF prevalence were included 
in the Poisson model. To account for between- CCG variation, 
CCGs were included as a random intercept. Year was included 
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as a continuous variable. Results are presented as incidence rate 
ratios with 95% CIs.
Comparisons of total prescribing costs, per- patient care costs 
for AF- related stroke and all care between the two study periods 
were undertaken to understand the budget impact of oral anti-
coagulation use. Data are presented as absolute and percentage 
changes, and incremental costs are shown for the cost of oral 
anticoagulation prescribing alone and for the cost of stroke 
management plus oral anticoagulation prescribing.
All analyses were performed using R V.3.5.1 with a signifi-
cance threshold of p=0.05.
RESULTS
We obtained ePACT data from a mean of 8601 GP practices and 
QOF data from a mean of 8256 practices (online supplemental 
table S6). HES data were collected from 200 hospitals per year.
Without adjustment for AF prevalence, the incidence of 
AF- related stroke did not differ significantly between the periods 
2011–2014 and 2014–2017 (figure 1A and online supplemental 
figures S1 and S2). After adjustment, the incidence of hospitalised 
AF- related stroke was significantly lower in 2014–2017 than in 
2011–2014 (p<0.001, figure 1B). The lowest incidence of hospi-
talised AF- related stroke across CCGs was five strokes per year 
and the highest was 575 per year (median 108, IQR 77–150). 
Significantly more oral anticoagulant items were prescribed for 
patients with AF in 2014–2017 than in 2011–2014, irrespective 
of AF prevalence (unadjusted median 77 278 for 2011–2014 vs 
128 129 for 2014–2017; adjusted median 73 368 for 2011–2014 
vs 104 680 for 2014–2017; all p<0.001; figure 1C,D).
The number of warfarin items prescribed increased by 5.9% 
(95% CI 2.9% to 8.9%) in 2014–2017 compared with 2011–
2014 (figure 2A). By contrast, the number of DOAC items 
prescribed rose by 2004.8% (95% CI 1848.8 to 2160.7%, 
figure 2B).
The incidence of hospitalised AF- related stroke increased with 
time (table 1), but the proportion of DOAC items prescribed 
reduced the incidence of all AF- related stroke and ischaemic 
AF- related stroke. No difference was seen for haemorrhagic 
AF- related stroke (table 1).
Changes in stroke incidence and associated budget impacts 
are shown in table 2. AF- related stroke incidence fell by 11.3% 
(95% CI –11.1% to –11.5%) after being adjusted for AF prev-
alence. The calculated total spend on management in the year 
after stroke also fell by 11.3% (95% CI –11.1% to –11.5%). 
Between the two periods, there was a small change in the 
number of people receiving warfarin for AF, but those receiving 
DOACs increased by 1452.7%. The cost of DOAC prescriptions 
increased by 1273.7%, leading to an overall increase in spending 
on oral anticoagulant prescriptions of 781.2%. Consequently, 
these changes led to budget impact for costs of oral anticoagu-
lant prescriptions and monitoring of £733 466 204.
When per- patient costs within the two study periods were 
considered, the cost of oral anticoagulant prescriptions alone led 
to an incremental increase of £149 per patient in 2014–2017. 
Figure 1 Incidence of hospitalised AF- related stroke and number of oral anticoagulant items prescribed in 2011–2014 vs 2014–2017, ranked by size 
of clinical commissioning group. (A) Unadjusted numbers of AF- related strokes. (B) Numbers of AF- related strokes adjusted for annual AF prevalence. 
(C) Unadjusted numbers of oral anticoagulant items prescribed for patients with AF. (D) Numbers of oral anticoagulant items prescribed for patients 
with AF adjusted for annual AF prevalence. Hospitalised patients with AF- related stroke had stroke as a primary diagnosis and AF as a secondary 
diagnosis recorded in the Hospital Episode Statistics database. Stroke incidence was adjusted for the AF prevalence reported per year in the Quality 
and Outcomes Framework, compared with the level at 2011. The red and black curves represent the fitted incidence or number of items for the two 
study periods, and the grey areas represent the 95% confidence bands. AF, atrial fibrillation.
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However, after taking into account the fall in the cost of manage-
ment in the first year after hospitalised AF- related stroke, the 
incremental overall cost of care fell in 2014–2017 to £289 below 
that in 2011–2014, leading to an incremental saving per patient 
at the national level.
DISCUSSION
Statement for principal findings
In this nationwide multisource health records evaluation, a 
substantial change in the number of DOAC prescriptions was 
seen in 2014–2017 compared with in 2011–2014, but little 
change was seen in the number of warfarin prescriptions. The 
associated overall budget impact of the changes in the numbers 
of oral anticoagulant prescriptions and INR monitoring was 
£733,466,204. Nevertheless, when the 11.3% reduction in 
AF- related stroke incidence was considered, an incremental per- 
patient saving to the overall healthcare system in England was 
seen (figure 3). More work is needed to investigate the patterns 
highlighted by this study.
The substantial budget impact that we calculated in relation to 
DOAC prescribing is an important consideration for healthcare 
services. Not only are more patients with AF being treated, but 
also adoption of the CHA2DS2–VASc (congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, stroke or tran-
sient ischaemic attack, vascular disease, age 65–74 years, sex 
category) score has broadened the threshold for identification 
of patients with AF at high risk of stroke and extended the pool 
eligible to receive oral anticoagulation.23 International guidance 
now recommends DOACs preferentially, and the number of 
new patients starting warfarin is falling.22 Although in this anal-
ysis the overall prevalence of warfarin prescription was higher 
than that of DOACs, this may change in the future. Because the 
cost of INR monitoring does not alter, the cost- effectiveness of 
warfarin prescribing is likely to decline as fewer patients require 
monitoring.
For the early period of our study, use of oral anticoagulation 
to treat AF was low in patients deemed to be at high risk of 
stroke despite assessment by CHA2DS2–VASc score or its prede-
cessor CHADS2 (congestive heart failure, hypertension, age ≥75 
years, diabetes mellitus, stroke (double weight)).24 25 Warfarin 
prescribing has also been noted to be inappropriately low in some 
subgroups of patients with AF at high risk of stroke yet over-
prescribed for some subgroups at low risk of stroke.25 Several 
national quality improvement initiatives, including changes to 
QOF in 2012, were made to incentivise GPs to use oral anticoag-
ulants in preference to antiplatelet agents in patients with AF at 
high risk of stroke. This is illustrated in our study by the finding 
that around 1 million additional people with AF received oral 
anticoagulants in the latter period, substantially exceeding the 
prevalence rise of 351 165 patients with AF in the same period 
(see online supplemental table S4). This substantial rise in oral 
anticoagulant use was due partly to DOACs being increasingly 
prescribed to people newly diagnosed with AF22 26 and to elderly 
and/or frail patients.27 This finding suggests that the important 
opportunity gap for treatment is being successfully closed.
Finally, this analysis supports the use of DOACs for stroke 
prevention in real- world clinical practice. Increased uptake was 
found to impact on AF- related stroke with no effect on the rate 
of intracranial haemorrhage. This latter finding is in contrast 
to meta- analyses, which have indicated reductions in haemor-
rhagic stroke with increased DOAC use.28 29 The reasons for this 
difference are unclear. The overall stroke reduction might have 
been influenced by the uptake of DOACs for higher- risk groups 
of patients or by the increased uptake of oral anticoagulation 
therapy in general. Another possibility is that DOACs might 
have a more specific clinical benefit than vitamin K antagonists 
in real- world clinical practice that was not seen in randomised 
controlled trials, although the analyses do not enable us to distin-
guish between these possibilities.
Figure 2 Total numbers of warfarin (A) and direct oral anticoagulant 
(B) items prescribed for patients with AF in 2011–2014 vs 2014–2017, 
ranked by size of clinical commissioning group. Data are derived from 
the National Health Service Business Services Authorities electronic 
Prescribing and Costing Tool. The red and black curves represent the 
fitted incidence or number of items for the two study periods, and the 
grey areas represent the 95% confidence bands.
Table 1 Incidence rate ratios and 95% CIs for the impact of time and 
the proportion of DOAC items prescribed on hospitalised AF- related 
stroke incidence
All strokes*
Ischaemic 
strokes*
Haemorrhagic 
strokes*
Year† 1.08 (1.06 to 1.10) 1.12 (1.09 to 1.15) 1.07 (0.99 to 1.14)
DOAC proportion 0.91 (0.84 to 0.98) 0.93 (0.86 to 0.99) 0.99 (0.74 to 1.33)
*Defined as stroke as the primary diagnosis and AF as the secondary diagnosis 
recorded in the Hospital Episode Statistics database. Each model was adjusted for 
annual AF prevalence, and each CCG was included as a random intercept to account 
for between- CCG variation.
†Year was included as a continuous variable.
AF, atrial fibrillation; DOAC, direct oral anticoagulant.
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Limitations
The study has various strengths, such as the 6- year study period, 
being a national level analysis and including data from multiple 
sources. However, it also has several important limitations. 
Stroke data in HES and prescribing data in ePACT are not 
linked, and the clinical condition for which a drug is prescribed 
is not indicated in ePACT. Therefore, we could not calculate 
accurately the numbers of people who were prescribed each drug 
type. We estimated the annual percentage of oral anticoagulant 
use in patients with AF versus other conditions using data from 
multiple national primary care sources. The large dataset, which 
includes every HES- recorded AF- related stroke in England 
during the study, and the large quantity of prescribing data lend 
robustness to this analysis. However, without data on factors 
such as changes in population demographics and management 
of other connected long- term conditions, such as hypertension, 
by lifestyle changes, more general confounders than accounted 
for could have influenced the results. Another limitation is 
that the numbers of strokes in individual years were too low 
to show differences robustly, and we had to compare data from 
Table 2 Changes in hospitalised AF- related stroke incidence, prescribing of oral anticoagulants and budget impact
2011–2014 2014–2017 Change over study period (%) Change over study period
Hospitalised AF- related stroke
  Total number of strokes* 86 467 76 730 −11.3% (95% CI −11.5% to −11.1%) −9737 (95% CI −9943 to −9597)
  Cost of management in the first year after stroke (£)† 1 154 507 384 1 024 498 960 −11.3% (95% CI −11.5% to −11.1%) −130 008 424
Prescription of oral anticoagulants for patients with AF
  Number taking warfarin 1 313 544 1 525 674 16.1 212 130
  Number taking DOACs 67 626 1 049 995 1452.7 982 369
  Number taking any oral anticoagulation 1 381 170 2 575 669 86.5 1 194 499
  Cost of warfarin (NIC) (£) 34 223 701 40 169 526 17.4 5 945 825
  Estimated INR monitoring costs (£) 317 877 664 369 213 149 16.1 51 335 485
  Cost of DOACs (NIC) (£) 53 089 609 729 274 502 1273.7 676 184 893
  Cost of all oral anticoagulants (£) 87 313 310 769 444 028 781.2 682 130 718
  Cost of all oral anticoagulants plus monitoring (£) 405 190 974 1 138 657 177 181.0 733 466 204
Per- patient costs by study period
  Cost of all oral anticoagulant prescriptions (£) 293 442 50.7 149‡
  Cost of all oral anticoagulant prescriptions and management 
in the first year after hospitalised AF- related stroke (£)*
1129 840 −25.6 −289‡
Numbers are rounded.
*After adjustment for AF prevalence.
†Healthcare costs in the year after stroke, including ambulance transport, MRI or CT scans, thrombolysis, acute stroke unit care, rehabilitation stroke unit care, general medical 
ward care, community rehabilitation, general practitioner visits, secondary prevention and therapy for early supported discharge,17 based on a cost per patient of £13 452.18 19
‡Incremental change in cost per patient.
AF, atrial fibrillation; DOAC, direct oral anticoagulant; INR, international normalised ratio; NIC, net ingredient cost.
Figure 3 Overall percentage changes in numbers of patients and strokes and in total and incremental per- patient treatment costs between 2011–
2014 and 2014–2017. *Calculated as the total prescribing costs for direct oral anticoagulants, warfarin and international normalised ratio monitoring 
plus management in the first year after stroke. OAC, oral anticoagulation.
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two 3.5- year time periods. A third limitation is that because we 
were unable to attribute the number of strokes to either DOAC 
or warfarin separately, the association between strokes and 
DOAC uptake had to be estimated by Poisson regression. Being 
unable to link any causality, we could not adjust for the small 
proportions of non- stroke indications. Therefore, a formal cost- 
effectiveness calculation was inappropriate and the analyses are 
descriptive. Nevertheless, some patterns of interest emerged that 
suggest further economic analyses should be undertaken.
CONCLUSIONS
To our knowledge, this is the first nationwide investigation to 
assess how prescribing patterns for oral anticoagulation and 
AF- related stroke incidence have changed over time and to 
consider the potential clinical and budgetary impacts. On initial 
review, the decline in stroke incidence seems to be at the cost of 
a large direct budget impact. However, because adjustment for 
annual change in AF prevalence lowered the incidence of hospi-
talised AF- related stroke in 2014–2017, per- patient costs were 
reduced at the national level. Stroke reduction may be improved 
further by better detection, starting more patients on treat-
ment and optimising treatment,30 and the cost- effectiveness of 
addressing these opportunities with DOACs should be assessed.
Key messages
What is already known on this subject?
 ► Given the rising prevalence of atrial fibrillation (AF) with the 
ageing population, clear understanding of how resources are 
used and the effects on population health is needed.
What might this study add?
 ► The UK is unique in that various national primary and 
secondary care databases exist in which prospectively 
collected data relating to clinical care and health outcomes 
over many years are collated and presented in consistent 
data fields. These data were used to assess in a novel way 
temporal changes in oral anticoagulation prescribing and 
AF- related stroke incidence, along with clinical and budget 
impacts during the same period.
How might this impact on clinical practice?
 ► On initial review, the decline in stroke incidence seemed to be 
achieved at the cost of a large direct budget impact. However, 
because adjustment for annual change in AF prevalence 
lowered the incidence of hospitalised AF- related stroke in 
2014–2017, per- patient cost reductions were revealed at the 
national level, which might be an important determinant in 
the wider implementation of oral anticoagulation for stroke 
prevention.
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